Drug Profile
Research programme: cancer stem cell-targeted therapeutics - Summit
Alternative Names: Targeting Cancer Stem Cells for Therapy - EuroCSCLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cancer Research UK; EuroCSC; European Molecular Biology Laboratory; Lund University; Medical Research Council; University of Copenhagen; University of Oxford; VASTox
- Class
- Mechanism of Action Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in European Union
- 20 Jul 2007 VASTox is now called Summit